This study provides evidence that a subset of breast cancer patients with a better prognosis a priori, such as patients with Luminal carcinomas, with or without Her2 positivity, can be stratified by their likelihood to develop BrM if FN14 is overexpressed (OR = 36.70). Here, ERBB2 is linked to breast cancer.